Cell replacement therapy in Parkinson's disease (PD) has so far been based on the use of
primary dopaminergic (DA) neuroblasts obtained from the brain of aborted human fetuses …

Clinical studies with intrastriatal transplants of human embryonic mesencephalic tissue have
provided proof-of-principle for the cell replacement strategy in Parkinson's disease (PD) …

Early clinical trials designed to treat Parkinson's disease by transplantation of fetal tissue
containing dopamine neuron precursors yielded promising results, but the approach retains …

A new therapeutic neurological and neurosurgical methodology involves cell implantation
into the living brain in order to replace intrinsic neuronal systems, that do not spontaneously …

The clinical studies with intrastriatal transplants of fetal mesencephalic tissue in Parkinson's
disease (PD) patients have provided proof-of-principle for the cell replacement strategy in …

The clinical trials with intrastriatal transplantation of human fetal mesencephalic tissue, rich
in dopaminergic neurons, in Parkinson's disease (PD) patients show that cell replacement …

Transplantation of fetal dopaminergic (DA) neurons can produce symptomatic relief for
patients with Parkinson's disease, but the technical and ethical difficulties have limited the …

The main pathology underlying motor symptoms in Parkinson's disease (PD) is a rather
selective degeneration of nigrostriatal dopamine (DA) neurons. Intrastriatal transplantation …

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the
degeneration of the dopamine producing neurons projecting from the substantia nigra into …

Current approaches to cell replacement therapy in Parkinson's disease are strongly focused
on the dopamine system, with the view that restoring dopaminergic inputs in a localized and …